nach oben

Erschienen in:

01.07.2017 | Original Paper

Aberrant gene promoter methylation of E-cadherin, p16 ^INK4a, p14 ^ARF, and MGMT in Epstein–Barr virus-associated oral squamous cell carcinomas

verfasst von: Ati Burassakarn, Chamsai Pientong, Nuchsupha Sunthamala, Jureeporn Chuerduangphui, Patravoot Vatanasapt, Natcha Patarapadungkit, Bunkerd Kongyingyoes, Tipaya Ekalaksananan

Erschienen in: Medical Oncology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

The etiology of oral carcinogenesis appears to be multifactorial. There is emerging evidence of the presence of Epstein–Barr virus (EBV) in epithelial oral squamous cell carcinoma (OSCC), but an association of EBV with oral carcinogenesis has not yet been established. Although epigenetic alterations, such as aberrant DNA methylation, are known to contribute to the pathogenesis of oral cancer, the relationship of such alterations with EBV infection is little known. This study aimed to investigate the association between EBV infection and promoter methylation patterns of tumor-associated genes in OSCC tissues. A total of 165 of formalin-fixed paraffin-embedded OSCC tissues were studied (68 of EBV positive and 97 of EBV negative). The promoter methylation patterns were investigated for four tumor-associated genes, E-cadherin, p16 ^INK4a, p14 ^ARF, and MGMT, by using methylation-specific polymerase chain reaction (MSP). The frequencies of gene promoter hypermethylation in all cases were 47.3% for E-cadherin, 92.7% for p16 ^INK4a, 74.5% for p14 ^ARF, and 35.8% for MGMT. Interestingly, most of the analyzed gene promoters were more frequently hypermethylated in EBV-positive than EBV-negative cases, in particular the E-cadherin (56/22) and MGMT (38/21) gene promoters (p < 0.05). Concomitantly, hypermethylation of multiple gene promoters (≥3) was encountered more frequently in EBV-positive samples. Hypermethylation of the E-cadherin promoter associated with EBV was more frequently observed in moderately and poorly differentiated OSCC tissues. These results indicate that epigenetic changes frequently occur in OSCCs and may partly be induced by EBV infection, therefore, EBV may involve in development and progression of the OSCCs.

Nur mit Berechtigung zugänglich

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi:10.1002/ijc.29210.CrossRefPubMed

Parkin DM, Stjernsward J, Muir CS. Estimates of the worldwide frequency of twelve major cancers. Bull World Health Organ. 1984;62(2):163–82.PubMedPubMedCentral

Scully C, Bagan J. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis. 2009;15(6):388–99. doi:10.1111/j.1601-0825.2009.01563.x.CrossRefPubMed

Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol. 2009;45(4–5):301–8. doi:10.1016/j.oraloncology.2009.01.004.CrossRefPubMed

Bagan JV, Scully C. Recent advances in Oral Oncology 2008; squamous cell carcinoma aetiopathogenesis and experimental studies. Oral Oncol. 2009;45(7):e45–8. doi:10.1016/j.oraloncology.2008.12.012.CrossRefPubMed

Sand L, Wallstrom M, Hirsch JM. Smokeless tobacco, viruses and oral cancer. Oral Health Dental Manag. 2014;13(2):372–8.

Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982–1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(6):622–35. doi:10.1067/moe.2001.115392.CrossRefPubMed

Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res. 2002;8(10):3187–92.PubMed

Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467–75. doi:10.1158/1055-9965.EPI-04-0551.CrossRefPubMed

10.

Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol. 2006;24(17):2606–11. doi:10.1200/JCO.2006.06.1291.CrossRefPubMedPubMedCentral

11.

Syrjanen S. Viral infections in oral mucosa. Scand J Dent Res. 1992;100(1):17–31.PubMed

12.

Sand L, Jalouli J. Viruses and oral cancer. Is there a link? Microbes Infect/Institut Pasteur. 2014;16(5):371–8. doi:10.1016/j.micinf.2014.02.009.CrossRef

13.

Jalouli J, Ibrahim SO, Sapkota D, Jalouli MM, Vasstrand EN, Hirsch JM, et al. Presence of human papilloma virus, herpes simplex virus and Epstein–Barr virus DNA in oral biopsies from Sudanese patients with regard to toombak use. J Oral Pathol Med. 2010;39(8):599–604. doi:10.1111/j.1600-0714.2010.00910.x.CrossRefPubMed

14.

Jalouli J, Ibrahim SO, Mehrotra R, Jalouli MM, Sapkota D, Larsson PA, et al. Prevalence of viral (HPV, EBV, HSV) infections in oral submucous fibrosis and oral cancer from India. Acta Otolaryngol. 2010;130(11):1306–11. doi:10.3109/00016481003782041.CrossRefPubMed

15.

Acharya S, Ekalaksananan T, Vatanasapt P, Loyha K, Phusingha P, Promthet S, et al. Association of Epstein–Barr virus infection with oral squamous cell carcinoma in a case-control study. J Oral Pathol Med. 2015;44(4):252–7. doi:10.1111/jop.12231.CrossRefPubMed

16.

de Groot JS, Pan X, Meeldijk J, van der Wall E, van Diest PJ, Moelans CB. Validation of DNA promoter hypermethylation biomarkers in breast cancer—a short report. Cell Oncol. 2014;37(4):297–303. doi:10.1007/s13402-014-0189-1.CrossRef

17.

Yiannakopoulou E. Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents—implications for cancer treatment and chemoprevention. Cell Oncol. 2014;37(3):167–78. doi:10.1007/s13402-014-0175-7.CrossRef

18.

Singal R, Ginder GD. DNA methylation. Blood. 1999;93(12):4059–70.PubMed

19.

Baylin SB. Tying it all together: epigenetics, genetics, cell cycle, and cancer. Science. 1997;277(5334):1948–9.CrossRefPubMed

20.

Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16(4):168–74.CrossRefPubMed

21.

Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–54. doi:10.1056/NEJMra023075.CrossRefPubMed

22.

Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 2003;4(6):351–8.CrossRefPubMed

23.

Yousuf A, Bhat MY, Pandith AA, Afroze D, Khan NP, Alam K, et al. MGMT gene silencing by promoter hypermethylation in gastric cancer in a high incidence area. Cell Oncol. 2014;37(4):245–52. doi:10.1007/s13402-014-0179-3.CrossRef

24.

Duijkers FA, de Menezes RX, Goossens-Beumer IJ, Stumpel DJ, Admiraal P, Pieters R, et al. Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines. Cell Oncol. 2013;36(5):351–62. doi:10.1007/s13402-013-0140-x.CrossRef

25.

D’Souza W, Saranath D. Clinical implications of epigenetic regulation in oral cancer. Oral Oncol. 2015;51(12):1061–8. doi:10.1016/j.oraloncology.2015.09.006.CrossRefPubMed

26.

Arantes LM, de Carvalho AC, Melendez ME, Carvalho AL, Goloni-Bertollo EM. Methylation as a biomarker for head and neck cancer. Oral Oncol. 2014;50(6):587–92. doi:10.1016/j.oraloncology.2014.02.015.CrossRefPubMed

27.

Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS. The Epstein–Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci USA. 2002;99(15):10084–9. doi:10.1073/pnas.152059399.CrossRefPubMedPubMedCentral

28.

Leal M, Lima E, Silva P, Assumpcao P, Calcagno D, Payao S, et al. Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil. World J Gastroenterol. 2007;13(18):2568–74.CrossRefPubMedPubMedCentral

29.

Supic G, Kozomara R, Brankovic-Magic M, Jovic N, Magic Z. Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol. 2009;45(12):1051–7. doi:10.1016/j.oraloncology.2009.07.007.CrossRefPubMed

30.

Wong TS, Tang KC, Kwong DL, Sham JS, Wei WI, Kwong YL, et al. Differential gene methylation in undifferentiated nasopharyngeal carcinoma. Int J Oncol. 2003;22(4):869–74.PubMed

31.

Zheng Z, Pan J, Chu B, Wong YC, Cheung AL, Tsao SW. Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol. 1999;30(4):458–66.CrossRefPubMed

32.

Krishna SM, Kattoor J, Balaram P. Down regulation of adhesion protein E-cadherin in Epstein–Barr virus infected nasopharyngeal carcinomas. Cancer Biomark. 2005;1(6):271–7.CrossRefPubMed

33.

Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res. 2002;8(1):131–7.PubMed

34.

Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Can Res. 2000;60(4):892–5.

35.

Dhiab MB, Ziadi S, Mestiri S, Gacem RB, Ksiaa F, Trimeche M. DNA methylation patterns in EBV-positive and EBV-negative Hodgkin lymphomas. Cell Oncol. 2015;38(6):453–62. doi:10.1007/s13402-015-0242-8.CrossRef

36.

Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–7. doi:10.1038/366704a0.CrossRefPubMed

37.

Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Can Res. 1995;55(20):4525–30.

38.

Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1(7):686–92.CrossRefPubMed

39.

Al-Kaabi A, van Bockel LW, Pothen AJ, Willems SM. p16INK4A and p14ARF gene promoter hypermethylation as prognostic biomarker in oral and oropharyngeal squamous cell carcinoma: a review. Dis Markers. 2014;2014:260549. doi:10.1155/2014/260549.CrossRefPubMedPubMedCentral

40.

De Schutter H, Geeraerts H, Verbeken E, Nuyts S. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. Oncol Rep. 2009;21(2):507–13.PubMed

41.

Ohta S, Uemura H, Matsui Y, Ishiguro H, Fujinami K, Kondo K, et al. Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(1):81–91. doi:10.1016/j.tripleo.2008.08.027.CrossRefPubMed

42.

Lim KP, Sharifah H, Lau SH, Teo SH, Cheong SC. Alterations of the p14ARF-p53-MDM2 pathway in oral squamous cell carcinoma: MDM2 overexpression is a common event. Oncol Rep. 2005;14(4):963–8.PubMed

43.

Smeds J, Berggren P, Ma X, Xu Z, Hemminki K, Kumar R. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF)) and p53 genes are major targets for inactivation. Carcinogenesis. 2002;23(4):645–55.CrossRefPubMed

44.

Ishida E, Nakamura M, Ikuta M, Shimada K, Matsuyoshi S, Kirita T, et al. Promotor hypermethylation of p14ARF is a key alteration for progression of oral squamous cell carcinoma. Oral Oncol. 2005;41(6):614–22. doi:10.1016/j.oraloncology.2005.02.003.CrossRefPubMed

45.

Ruesga MT, Acha-Sagredo A, Rodriguez MJ, Aguirregaviria JI, Videgain J, Rodriguez C, et al. p16(INK4a) promoter hypermethylation in oral scrapings of oral squamous cell carcinoma risk patients. Cancer Lett. 2007;250(1):140–5. doi:10.1016/j.canlet.2006.10.001.CrossRefPubMed

46.

Xing XB, Cai WB, Luo L, Liu LS, Shi HJ, Chen MH. The prognostic value of p16 hypermethylation in cancer: a meta-analysis. PLoS ONE. 2013;8(6):e66587. doi:10.1371/journal.pone.0066587.CrossRefPubMedPubMedCentral

Titel: Aberrant gene promoter methylation of E-cadherin, p16 INK4a , p14 ARF , and MGMT in Epstein–Barr virus-associated oral squamous cell carcinomas
verfasst von: Ati Burassakarn
Chamsai Pientong
Nuchsupha Sunthamala
Jureeporn Chuerduangphui
Patravoot Vatanasapt
Natcha Patarapadungkit
Bunkerd Kongyingyoes
Tipaya Ekalaksananan
Publikationsdatum: 01.07.2017
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 7/2017
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-017-0983-5

Springer Medizin

Aberrant gene promoter methylation of E-cadherin, p16 ^INK4a, p14 ^ARF, and MGMT in Epstein–Barr virus-associated oral squamous cell carcinomas

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2017

Advances in systemic therapy for metastatic breast cancer: future perspectives

Clinical significance of androgen secretion disorders in men with a malignancy

Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy

Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives

Downregulation of TRPM7 suppressed migration and invasion by regulating epithelial–mesenchymal transition in prostate cancer cells

Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie